Results 211 to 220 of about 18,044 (238)
Some of the next articles are maybe not open access.
Expert Opinion on Biological Therapy, 2012
Until now most insulin used in developed countries is manufactured and distributed by a small number of multinational companies. Other pharmaceutical companies - many of these are located in countries such as India or China - are also able to manufacture insulin with modern biotechnological methods.
openaire +2 more sources
Until now most insulin used in developed countries is manufactured and distributed by a small number of multinational companies. Other pharmaceutical companies - many of these are located in countries such as India or China - are also able to manufacture insulin with modern biotechnological methods.
openaire +2 more sources
2017
Biosimilars are a new class of drugs, which are derived from live organism through the recombinant DNA technology. These are recently introduced in the pharmaceutical field for the preparation of drug to prevent or control the diseases. Patients with diabetes and renal failure may already be receiving biosimilar epoetin and may receive same insulin in ...
Anil K. Sharma +2 more
openaire +2 more sources
Biosimilars are a new class of drugs, which are derived from live organism through the recombinant DNA technology. These are recently introduced in the pharmaceutical field for the preparation of drug to prevent or control the diseases. Patients with diabetes and renal failure may already be receiving biosimilar epoetin and may receive same insulin in ...
Anil K. Sharma +2 more
openaire +2 more sources
Biosimilar anti-VEGF—Yardsticks to ensure biosimilarity
Eye, 2022Ashish Sharma +4 more
openaire +3 more sources
Biosimilars accessible in the market for the treatment of cancer
Journal of Controlled Release, 2021Neelima Anup +2 more
exaly
Biosimilars: the impact of their heterogeneity on regulatory approval
Nature Reviews Drug Discovery, 2007Asterios S Tsiftsoglou
exaly +2 more sources
Challenges for biosimilars: focus on rheumatoid arthritis
Critical Reviews in Biotechnology, 2021Muhammad Safwan Akram +2 more
exaly
Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars
Nature Reviews Drug Discovery, 2012John R Engen, Graham B Jones
exaly